Research Article

Baker’s Yeast Sensitizes Metastatic Breast Cancer Cells to Paclitaxel In Vitro

Nariman K. Badr El-Din, PhD¹, Ashraf Z. Mahmoud, PhD¹, Tahia Ali Hassan, MS¹, and Mamdooh Ghoneum, PhD²

Abstract

Our earlier studies have demonstrated that phagocytosis of baker’s yeast (Saccharomyces cerevisiae) induces apoptosis in different cancer cell lines in vitro and in vivo. This study aimed to examine how baker’s yeast sensitizes murine and human breast cancer cells (BCC) to paclitaxel in vitro. This sensitizing effect makes lower concentrations of chemotherapy more effective at killing cancer cells, thereby enhancing the capacity of treatment. Three BCC lines were used: the metastatic murine 4T1 line, the murine Ehrlich ascites carcinoma (EAC) line, and the human breast cancer MCF-7 line. Cells were cultured with different concentrations of paclitaxel in the presence or absence of baker’s yeast. Cell survival and the IC₅₀ values were determined by MTT assay and trypan blue exclusion method. Percent of DNA damage, apoptosis, and cell proliferation were examined by flow cytometry. Yeast alone and paclitaxel alone significantly decreased 4T1 cell viability postculture (24 and 48 hours), caused DNA damage, increased apoptosis, and suppressed cell proliferation. Baker’s yeast in the presence of paclitaxel increased the sensitivity of 4T1 cells to chemotherapy and caused effects that were greater than either treatment alone. The chemosensitizing effect of yeast was also observed with murine EAC cells and human MCF-7 cells, but to a lesser extent. These data suggest that dietary baker’s yeast is an effective chemosensitizer and can enhance the apoptotic capacity of paclitaxel against breast cancer cells in vitro. Baker’s yeast may represent a novel adjuvant for chemotherapy treatment.

Keywords
Saccharomyces cerevisiae, apoptosis, paclitaxel, breast cancer, 4T1

Received May 9, 2017; revised September 16, 2017; accepted September 25, 2017

Introduction

Chemotherapy is currently the mainstay of treatment for most types of cancer, with agents exerting their anticancer effect by inducing apoptosis.¹,² One such drug currently in use is paclitaxel. Paclitaxel is most often used for the treatment of breast cancer, ovarian cancer, non–small cell lung cancer, and AIDS-related Kaposi’s sarcoma.³ Paclitaxel is able to induce the mitochondrial apoptotic pathway in various cancer cell types. Paclitaxel induces the mitochondrial permeability transition, triggering the release of prodeath molecules (Bax and Bad, which then inactivate Bcl-2 or Bcl-x₁) and activating caspases, which then induce apoptosis of neoplastic cells.⁴,⁵ Chemotherapy drugs can be effective in treating cancer; however, many chemotherapeutic agents exhibit dose-limiting toxicities, which can cause congestive heart failure, myelosuppression, neurotoxicity, immune-suppression, and mutagenic and carcinogenic effects.⁶-¹⁰ Many attempts have been made to circumvent the toxic effects of chemotherapy, including using chemosensitizers, which make tumor cells more sensitive to the effects of chemotherapy and therefore require lower doses of the toxic chemotherapeutic drugs. In the past 40 years, research has focused on the development of potent therapies to circumvent multidrug resistance (MDR), and several chemosensitizing agents have been discovered which enhance the cytotoxic effect of chemotherapy drugs in cancer cells; these include the calcium blockers diltiazem, the biscoclaurine alkaloid cepharanthine, and verapamil¹¹-¹⁴; the anti-arrhythmic agent quinidine¹⁵; and the synthetic isothiocyanate derivative E-4IB.¹⁶ However, these agents are also toxic. Calcium antagonist poisoning is well documented, and other

¹University of Mansoura, Mansoura, Egypt
²Drew University of Medicine and Science, Los Angeles, CA, USA

Corresponding Author:
Nariman K. Badr El-Din, Department of Zoology, Faculty of Science, University of Mansoura, Mansoura 35516, Egypt.
Email: na_ri_eg@yahoo.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
side effects may include dizziness, headache, redness in the face, fluid buildup in the legs and ankles, abnormal heart rate, constipation, and gingival overgrowth.17,18

Recently, several researchers have focused on screening for nontoxic natural modulators to overcome ABC transporter-mediated MDR. Two natural products, curcumin and flavonoids, have been extensively studied in the context of modulation of MDR transporter expression.19,20 In addition, work from our laboratory has introduced a novel, natural, dietary product, arabinoxylan rice bran (MGN-3/Biobran), which when combined with chemotherapy allowed for lowering the drug concentration used during treatment, thereby reducing the toxicity of chemotherapy while maintaining potency against cancer cells in vitro and in vivo.21-23 In this study, we evaluated the ability of another dietary product, baker’s and brewer’s yeast, *Saccharomyces cerevisiae*, to sensitize cancer cells to chemotherapy in vitro. *S. cerevisiae* is a potent apoptotic agent against cancer cells. Cancer cells undergo apoptosis upon phagocytosis of *S. cerevisiae*. Baker’s yeast can induce apoptosis in several human cancer cell lines, including breast, tongue, and colon cells in vitro.24-27 Yeast can also exert anticancer effects in nude mice bearing human breast cancer28,29 and in Swiss albino mice bearing Ehrlich carcinoma.30

Our results reveal that *S. cerevisiae* induces anticancer effects in murine and human breast cancer cells and, when combined with paclitaxel, induces killing of a greater number of cancer cells than either yeast or paclitaxel used alone. These results suggest that baker’s yeast may be used as an adjuvant during chemotherapy treatment and may have clinical implications for the treatment of breast cancer.

**Materials and Methods**

**Drugs and Chemicals**

Paclitaxel was purchased from Bristol-Myers Squibb Inc (Princeton, NJ, USA). It was supplied with initial concentration of 100 mg/16.7 mL. Each milliliter of sterile nonpyrogenic solution contains 6 mg paclitaxel, 527 mg of purified Cremophor EL (polyoxymethylated castor oil), and 49.7% (v/v) dehydrated alcohol, USP. RPMI-1640 supplemented with 10% fetal calf serum (FCS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) from Sigma-Aldrich.

**Preparation of Saccharomyces cerevisiae**

Commercially available baker’s and brewer’s yeast, *S. cerevisiae*, was used in suspensions that were washed once with phosphate-buffered saline (PBS). It was then incubated for 1 hour at 90°C to kill the yeast and washed 3 times with PBS. Quantification was carried out using a hemocytometer, and cell suspensions were adjusted to 1 × 10^4, 1 × 10^5, 1 × 10^6, 1 × 10^7, 1 × 10^8, and 1 × 10^9 cells/mL.

**Breast Cancer Cell Lines and Culture Conditions**

Three breast cancer cell (BCC) lines were used in the study: the highly metastatic murine 4T1 line; the murine Ehrlich ascites carcinoma (EAC) cell line, a mammary adenocarcinoma; and the human nonmetastatic breast cancer MCF-7 line. 4T1 and MCF-7 cells were purchased from the American Tissue and Culture Collection (ATCC; Manassas, VA, USA). 4T1 and MCF-7 cells were maintained in our laboratory in a complete medium that consisted of RPMI-1640, supplemented with 10% FCS, 2 mM glutamine, and 100 µg/mL streptomycin and penicillin.

We chose MCF-7 as our human BCC line since MCF-7 cells have been found to be more susceptible to yeast-induced apoptosis as compared with other human BCC lines, including ZR-75 cells and HCC70 cells.24 Furthermore, MCF-7 cells proved to be potent phagocytic cells as exemplified by their ability to rapidly engulf, digest, and fragment yeast cells with lysosomal encirclement of the engulfed yeast cells.25,29

**Preparation of Ehrlich Ascites Carcinoma Cells**

The transplantable murine tumor cell line, namely EAC cells, was obtained from the National Cancer Institute, Cairo University, Egypt. The EAC cells were maintained in the ascitic form in vivo in Swiss albino mice by means of sequential intraperitoneal transplantation of 2 × 10^6 cells/mouse after every 10 days. Ascitic fluid was drawn out from EAC-bearing mouse 8 days after transplantation from the peritoneal cavity by aspirating the ascitic fluid into a sterile isotonic saline solution. The freshly drawn fluid was diluted with ice-cold sterile PBS (0.2 M, pH 7.4), and the tumor cell count was adjusted to 2 × 10^6 cells/mL by sterile PBS immediately before the studies.

**Effect of Paclitaxel Plus Yeast on Growth of Breast Cancer Cells**

**Drug Sensitivity Assay.** Drug sensitivity was determined by using a colorimetric MTT assay. Cancer cells (1 × 10^4 cells/well) were seeded in 96-well plates and cultured in triplicate with different concentrations of yeast (1 × 10^−6 to 1 × 10^−1 M/L) and in the presence or absence of paclitaxel at different concentrations (1 × 10^−6 to 1 × 10^−3 M/L). The final volume of medium in each well after the addition of yeast or paclitaxel was 200 µL. The cultures were incubated at 37°C for 24 and 48 hours, after which 50 µg of MTT were added to each well, and the cultures were incubated for an additional 4 hours. The plates were then centrifuged, the medium was carefully removed, the formazan crystals solubilized with acid alcohol, and the plates were read at 590 nm using an ELISA plate reader (Molecular Devices, Menlo Park, CA, USA). The 50% inhibitory concentration (IC_{50}) was determined as the drug concentration resulting in a
50% reduction of cell viability. The IC$_{50}$ was determined by plotting the logarithm of the drug concentration versus the survival rate of the treated cells.

**Trypan Blue Exclusion Method.** In sterile test tubes, the cells and chemicals were added with the aforementioned concentrations of yeast, paclitaxel, and both yeast plus paclitaxel in triplicates. Cells were incubated for 24 and 48 hours at 37°C in a humidified atmosphere of 5% CO$_2$ in sterile medium. Viable cells were counted by trypan blue exclusion using hemocytometer. Then the percentage of live cells was obtained by dividing the viable cells by the total number of cells. All experiments were repeated in triplicates.

**Flow Cytometric Analysis for Apoptosis, DNA Damage, and Cell Proliferation**

Quantitative detection of apoptosis, DNA damage, and cell proliferation in 4T1 cells treated with yeast with and without paclitaxel was simultaneously determined by multicolor flow cytometric analysis using the Apoptosis, DNA Damage and Cell Proliferation Kit specific for incorporated bromodeoxyuridine (BrdU), phosphorylated H2AX (#H2AX), and cleaved poly ADP ribose polymerase (PARP) (BD Biosciences Pharmingen, San Diego CA, USA). Following the manufacturer’s instructions, cells were cultured in a CM or with different concentrations of yeast (1 × 10$^7$ cells/mL) and (1 × 10$^9$ cells/mL) with and without paclitaxel (1 × 10$^{-3}$ M) for 24 or 48 hours. Ten microliters of BrdU working solution (1 mM BrdU in 1× [DPBS]) was added to each milliliter of tissue culture medium (the cell culture density was approximately 1 × 10$^6$ M) for 24 or 48 hours. Ten microliters of BrdU working solution (1 mM BrdU in 1× [DPBS]) was added to each milliliter of tissue culture medium (the cell culture density was approximately 1 × 10$^6$ cells/mL); following this, the cells were incubated for 30 minutes on ice. Cells were washed by adding 1 mL of staining buffer/test and centrifuged (5 minutes) at 250 × g, and the supernatant was discarded. Cells were fixed with 100 µL of BD Cytofix/Cytoperm Fixation/Permeabilization Solution per test and incubated for 30 minutes at room temperature. Afterward, cells were washed with 1 mL of 1× BD Perm/Wash Buffer, centrifuged, and the supernatant was discarded. Cells were incubated in 100 µL of BD Cytofix/Cytoperm Plus Permeabilization Buffer/ tube for 10 minutes in ice, washed, and then refixed for 5 minutes. One hundred microliters of diluted DNase were added to cells, which were incubated for 1 hour at 37°C and then washed. Cells were resuspended with 20 µL wash buffer plus PerCP-Cy 5.5 mouse anti-BrdU (5 µL/test), Alexa Fluor 647 mouse anti-H2AX (pS139) (5 µL/test), PE anti-cleaved PARP (Asp214) (5 µL/test) for 20 minutes in the dark and then washed. Cells were resuspended in staining buffer for analysis by fluorescence-activated cell sorting (FACSCalibur; BD Biosciences, San Jose, CA, USA) using CellQuest 3.3 software.$^{31,32}$

**Statistical Analysis**

Values are reported as the mean ± standard error (mean ± SE), and data were analyzed using 1-way analysis of variance followed by post hoc tests for multiple comparisons. A P value less than .05 was considered statistically significant.

**Results**

**Cytotoxicity of Yeast and Paclitaxel on Breast Cancer Cell Lines**

Cytotoxicity of yeast plus paclitaxel was examined against three BCC lines: the highly metastatic murine 4T1 line, the murine EAC cell line, and the human MCF-7 cell line. BCCs were cultured with paclitaxel at different concentrations (10$^{-6}$-10$^{-1}$ M/L) in the presence or absence of yeast at different concentrations (10$^4$-10$^9$ cells/mL). Results were evaluated with 2 different methods (MTT assay and Trypan blue exclusion method) at 24 and 48 hours incubation time before cell survival and the IC$_{50}$ values were determined.

**4T1 Cells.** 4T1 cells were incubated for 48 hours with paclitaxel and/or yeast, and cell survival was examined by MTT assay and IC$_{50}$ values were also determined (Figure 1A-D). Paclitaxel treatment alone (10$^{-7}$-10$^{-1}$ M/L) caused a decrease in 4T1 cell survival with IC$_{50}$ (5 × 10$^{-5}$ M/L) (Figure 1A). Data depicted in Figure 1B show that yeast treatment alone (10$^4$-10$^9$ cells/mL) resulted in decreasing the cell survival with IC$_{50}$ (2 × 10$^5$ cells/mL). On the other hand, data in Figure 1C show that the cytotoxicity of yeast at low concentration of 10$^7$ cells/mL in combination with paclitaxel at different concentrations (10$^{-6}$-10$^{-1}$ M/L) resulted in a significant decrease of 4T1 cell survival with IC$_{50}$ (5 × 10$^{-5}$ M/L). The cytotoxic effect of yeast at higher concentration of 10$^9$ cells/mL in combination with paclitaxel became more remarkable with IC$_{50}$ (2 × 10$^{-5}$ M/L) (Figure 1D). Similar results were obtained to a lesser extent at 24 hours. Similar results were noticed when Trypan blue exclusion method was used to determine the levels of toxicity by yeast and paclitaxel against 4T1 cells (data not shown).

**EAC Cell Line.** Data in Figure 2A-D show that the combination of yeast with paclitaxel induces higher cytotoxic effects on EAC cells than paclitaxel alone. The decrease in EAC cell survival postexposure to different treatments for 48 hours showed IC$_{50}$ = 6.86 × 10$^{-4}$ M/L for paclitaxel alone (Figure 2A), and IC$_{50}$ = (7 × 10$^6$ cells/mL) for yeast alone (Figure 2B). When paclitaxel was combined with yeast (10$^7$ cells/mL), IC$_{50}$ decreased to 3 × 10$^{-4}$ M/L (Figure 2C) and to 6 × 10$^{-5}$ M/L for 10$^9$ cells/mL of yeast (Figure 2D). Similar results, to a lesser extent, were obtained with yeast.
alone at 24 hours. Also, similar results were noticed when the Trypan blue exclusion method was used (data not shown).

**MCF-7 Cell Line.** The combined effect of paclitaxel and yeast also yielded a higher cytotoxic effect against human breast MCF-7 cells than either treatment alone. Results in Figure 3A and B show that the decrease in MCF-7 cell survival postexposure to different treatments for 48 hours was IC_{50} = 6 \times 10^{-4} \text{ M/L} for paclitaxel alone, and IC_{50} = 6.86 \times 10^{6} \text{ cells/mL} for yeast alone, respectively. When the 2 agents were combined, a significant decrease of MCF-7 cell survival was noticed with IC_{50} = 9 \times 10^{-5} \text{ M/L} for 1 \times 10^{7} \text{ cells/mL} yeast (Figure 3C), and IC_{50} = 4 \times 10^{-5} \text{ M/L} for 1 \times 10^{9} \text{ cells/mL} yeast (Figure 3D). Similar results were obtained to a lesser extent at 24 hours. Also, similar results were noticed when Trypan blue exclusion method was used to determine the levels of toxicity by yeast and paclitaxel against MCF-7 cells (data not shown).

**Flow Cytometry Analysis for the Evaluation of Cell Proliferation, DNA Damage, and Apoptosis**

Data in Figures 1-3 showed different responses among cell lines toward the cytotoxic effect of paclitaxel, yeast, and yeast plus paclitaxel. We observed the following pattern of sensitivity toward the cytotoxic effect of different treatments: 4T1 > MCF-7 > EAC cells, with 4T1 cells proving to be the most responsive. Therefore, the highly metastatic 4T1 cells were used to examine more detailed effects of different treatments, including DNA damage, apoptosis, and cell proliferation.

**DNA Damage of 4T1 Cells.** The effect of yeast at 2 different concentrations (1 \times 10^{7} and 1 \times 10^{9} \text{ cells/mL}) and/or paclitaxel (1 \times 10^{-3} \text{ M/L}) on percentage of DNA damage of 4T1 cells was examined. Data in Figure 4 show that treatment of 4T1 cells with paclitaxel alone significantly increased the percentage of DNA damage (94.3\%, \text{P} < .01), as compared
Integrative Cancer Therapies 17(2)

with control untreated 4T1 cells. Treatment with yeast at concentrations (1 × 10^7 and 1 × 10^9 cells/mL) resulted in 104.1% and 126.5% (P < .01), relative to control untreated cells, respectively. On the other hand, exposure of 4T1 cells to both paclitaxel plus yeast resulted in a marked increase in the percentage of DNA damage that was higher than with either agent alone. The chemosensitizing effect of yeast was significant at 24 hours and further increased at 48 hours.

**Apoptosis of 4T1 Cells.** The effect of yeast at 2 different concentrations (1 × 10^7 and 1 × 10^9 cells/mL) and/or paclitaxel (1 × 10^{-3} M/L) on the percentage of 4T1 cell apoptosis was examined. Data in Figure 5 show that treatment with paclitaxel alone increased 4T1 cell apoptosis at 48 hours (44.34%, P < .05). Yeast, in a dose-dependent manner, significantly enhanced apoptosis of 4T1 cells (53.87%, P < .01) and (93.95%, P < .01) at concentrations 1 × 10^7 and 1 × 10^9 cells/mL, respectively. However, exposure of 4T1 cells to yeast plus paclitaxel resulted in a higher percentage of 4T1 cell apoptosis: 124.7% (P < .01) at yeast concentration 1 × 10^7 cells/mL and 149.5% (P < .01 level) at yeast concentration 1 × 10^9 cells/mL as compared to control. The apoptotic effect of combined agents was higher than that with either agent alone. The apoptotic effect of yeast was significant at 24 hours and further increased at 48 hours.

**Proliferation of 4T1 Cells.** Figure 6 shows the effect of yeast at two concentrations (1 × 10^7 and 1 × 10^9 cells/mL) in the presence and absence of paclitaxel (1 × 10^{-3} M/L) on the percentage of 4T1 cell proliferation. Treatment of 4T1 cells with paclitaxel resulted in inhibition of cell proliferation at 48 hours (50.2%, P < .01), as compared with control untreated 4T1 cells. Similarly, 4T1 cell exposure to yeast alone caused a decrease in cell proliferation 48.4%, and 54.4% (P < .01) at yeast concentrations 1 × 10^7 and 1 × 10^9 cells/mL, respectively, as compared with control untreated

![Figure 2](image-url)
Badr El-Din et al

4T1 cells. However, co-culture of 4T1 cells in the presence of yeast plus paclitaxel showed significant inhibition of cell proliferation that was greater than either agent alone.

Discussion

Paclitaxel is considered to be a common chemotherapeutic drug for the treatment of breast cancer. It induces an apoptotic effect on cancer at high concentrations and, as a result, its treatment is associated with severe side effects, including gastrointestinal, pulmonary, and neuromuscular toxicities, as well as neutropenia, granulocytopenia, and hypotension. Therefore, we have focused our research on finding dietary agents that may have the ability to reduce the toxicity of chemotherapy by using lower drug concentrations while maintaining potency against cancer cells. Our recent studies revealed that arabinoxylan rice bran, Biobran/MGN-3, has the ability to sensitize cancer cells to chemotherapy agents daunorubicin and paclitaxel in vitro and in vivo. In addition, the ability of Biobran/MGN-3 to enhance the effects of interventional therapies for the treatment of hepatocellular carcinoma was examined in a 3-year randomized clinical trial. This previous trial revealed a higher survival rate and a lower percentage of recurrence in patients who received both interventional therapies and Biobran/MGN-3, as compared with chemotherapy alone. Other dietary products, such as fatty acids, also act as chemo- sensitizers by improving the cytotoxic effect of paclitaxel and increasing the intracellular chemotherapy drug accumulation in cancer cells. Data show that baker’s yeast is able to reduce the concentration of paclitaxel required for killing nonmetastatic and metastatic BCCs in vitro. The IC50 value for paclitaxel was significantly reduced against BCCs of human MCF-7, and murine 4T1, and EAC cells in the presence of yeast. Baker’s yeast can therefore potentially be used to reduce the chemotoxic effects of paclitaxel.

Figure 3. Effect of paclitaxel and yeast on the growth and viability of MCF-7 cells as assessed by MTT assay. MCF-7 cells were exposed for 24 and 48 hours to the following treatments: (A) paclitaxel alone, (B) yeast alone (1 × 10⁴ to 1 × 10⁹ cells/mL), (C) paclitaxel plus yeast (1 × 10⁷ cells/mL), and (D) paclitaxel plus yeast (1 × 10⁹ cells/mL). Data are the mean ± SE of 2 experiments performed in triplicate. **P < .01 and was considered as statistically significant.
Many anticancer drugs function by inducing apoptosis. Paclitaxel induces apoptosis in different cancer cells, including breast cancer, gastric cancer, colon cancer, and leukemia cells by modifying mitochondrial transition permeability, activating caspase-8 and caspase-3, and Bcl-2 inactivation by a mechanism that may involve the binding of paclitaxel to this antiapoptotic protein. As demonstrated in this study, heat-killed baker’s yeast also acts as an anticancer agent via induction of apoptosis. These results are in accordance with our earlier studies, which have shown that human breast, tongue, and colon cancer cells undergo apoptosis on phagocytosis of *S. cerevisiae* in vitro. Cancer cells treated with yeast showed clear signs of apoptosis, including nuclear fragmentation and membrane blebbing, significant decrease in the mitochondrial polarization, and increased activation of caspase-8, -9, and -3 in vitro. Furthermore, yeast induced extensive apoptosis in nude mice bearing human breast cancer and in mice bearing EAC, as determined by histopathological analysis and by flow cytometry.

Earlier studies have also shown that paclitaxel prevents cell proliferation by binding to tubulin in microtubules. This characteristic may explain the observed inhibition of cell proliferation and DNA damage in 4T1 cells treated with paclitaxel. In the present study, we also noted that exposure of 4T1 cells to paclitaxel plus yeast resulted in a marked inhibition of cell proliferation, significant increase in the percentage of DNA damage, and elevation of apoptotic cancer cells. The combined effects of both yeast and paclitaxel were more effective than that of either treatment alone. The underlying mechanisms by which yeast sensitizes cancer cells to chemotherapy are not fully understood, but they might be attributed to yeast’s ability to modulate one or more of the various transport proteins of the ABC superfamily. These proteins are responsible for MDR by decreasing the uptake of the drug or increasing the efflux of the drug from the target organelles. The phytochemical curcumin and phytochemical flavonoids have been described as natural modulators of MDR transporter expression. Curcumin and its metabolite tetrahydrocurcumin were used in restoring drug sensitivity in cancer cells overexpressing the MDR-linked ABC transporters MRP1, Pgp, and Bcl-2.
and ABCG2\textsuperscript{52} by directly inhibiting their functions. Similarly, flavonoids have been shown to be potent modulators of major ABC drug transporters.\textsuperscript{51,54}

Dietary agents such as Biobran/MGN-3 or the baker’s yeast studied here may provide safe, nontoxic avenues for effective therapies against MDR cancer cells. Studies have shown that yeast is not toxic to nontumorigenic breast epithelial (MCF-10A) cells.\textsuperscript{26} More studies are needed to explore the clinical significance of yeast treatment in different types of cancer. In our ongoing current studies, intratumoral injection of yeast, in combination with low doses of paclitaxel, has been found to significantly reduce tumor size in Ehrlich mammary adenocarcinoma bearing mice, as associated with the development of large degenerative necrotic regions in the tumor (unpublished data). In addition, intratumoral injection of yeast has also been found to be effective in inducing apoptotic effects against skin cancer in rats bearing tumor (unpublished data). We hope that these and other studies will prompt further investments toward studying the effectiveness of yeast treatment for patients with different types of malignancies.

In conclusion, the present study represents the first set of experiments demonstrating that dietary supplementation of baker’s yeast can enhance the apoptotic capacity of paclitaxel in breast cancer cells in vitro. These data suggest that baker’s yeast may be used as an adjuvant for chemotherapy treatment, which may have clinical implications for the treatment of breast cancer.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

1. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992;11:121-139.
2. Martin SJ, Green DR. Apoptosis as a goal of cancer therapy. Curr Opin Oncol. 1994;6:616-621.
3. Cancer Research UK. General cancer information. Paclitaxel (Taxol). http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/paclitaxel. Updated March 19, 2016. Accessed October 17, 2017.
4. Kolfschoten GM, Hulscher TM, Duyndam MC, Pinedo HM, Boven E. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem Pharmacol. 2002;63:733-743.
5. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 2001;28(4 suppl 15):3-7.
6. Yamaguchi H, Wang HG. Bel-4XL protects BinEL-induced Bax conformational change and cytochrome C release independent of interacting with Bax or BinEL. J Biol Chem. 2002;277:41604-41612.
7. Taillibert S, Le Rhun E, Chamberlain MC. Chemotherapy-related neurotoxicity. Curr Neurol Neurosci Rep. 2016;16:81.
8. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1999;339:906-905.
9. Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res. 1996;355:59-70.
10. Santin AD, Hermonat PL, Ravaggi A, et al. Effects of concurrent cisplatin administration during radiotherapy vs radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 2000;48:997-1006.
11. Kato T, Suzumura Y. Potentiation of antitumor activity of vincristine by the bisoclaurine alkaloid cepharanthine. J Natl Cancer Inst. 1987;79:527-532.
12. Yamamoto S, Hui PZ, Fukuda Y, Tatsumi K, Min M. Potentiation of harringtonine cytotoxicity by calcium antagonist diltiazem and bisoclaurine alkaloid cepharanthine in adriamycin-resistant P388 murine leukemia and K562 human leukemia cells. Biochem Int. 1989;18:1077-1083.
13. Nishikawa K, Asaumi J, Kawasaki S, Kuroda M, Takeda Y, Hiraki Y. Influence of cepharanthin on the intracellular accumulation of adriamycin in normal liver cells and spleen cells of mice in vitro and in vivo. Anticancer Res. 1997;17:3617-3621.
14. Tsuruo T, Iida H, Nagamama K, Tsukagoshi S, Sakurai Y. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res. 1983;43:808-813.
15. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 1984;44:4303-4307.
16. Bodo J, Hunakova L, Kvasnicka P, et al. Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations. Br J Cancer. 2006;95:1348-1353.
17. Pearigen PD, Benowitz NL. Poisoning due to calcium antagonists. Experience with verapamil, diltiazem, and nifedipine. Drug Saf. 1991;6:408-430.
18. Lip GY, Ferner RE. Poisoning with anti-hypertensive drugs: calcium antagonists. J Hum Hypertens. 1995;9:155-161.
19. Karthikeyan S, Hoti SL. Development of fourth generation ABC inhibitors from natural products: a novel approach to overcome cancer multidrug resistance. Anticancer Agents Med Chem. 2015;15:605-615.
20. Wu CP, Ohnuma S, Ambudkar SV. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2011;12:609-620.
21. Badr El-Din NK, Ali DA, Alaa El-Dein M, Ghoneum M. Enhancing the apoptotic effect of a low dose of paclitaxel on tumor cells in mice by arabinoxylan rice bran (MGN-3/Biobran). Nutr Cancer. 2016;68:1010-1020.
22. Gollapudi S, Ghoneum M. MGN-3/Biobran, modified arabinoxylan from rice bran, sensitizes human breast cancer cells to chemotherapeutic agent, daunorubicin. Cancer Detect Prev. 2008;32:1-6.
23. Ghoneum M, Badr El-Din NK, Ali DA, Alaa El-Dein M. Modified arabinoxylan from rice bran, MGN-3/Biobran, sensitizes metastatic breast cancer cells to paclitaxel in vitro. *Anticancer Res.* 2014;34:81-87.

24. Ghoneum M, Gollapudi S. Induction of apoptosis in human breast cancer cells by *Saccharomyces cerevisiae*, the baker’s yeast, in vitro. *Anticancer Res.* 2004;24:1455-1463.

25. Ghoneum M, Gollapudi S. Modified arabinoxylan rice bran (MGN-3/Biobran) enhances yeast-induced apoptosis in human breast cancer cells in vitro. *Anticancer Res.* 2005;25:859-870.

26. Ghoneum M, Gollapudi S. Synergistic role of arabinoxylan rice bran (MGN-3/Biobran) in *S. cerevisiae*-induced apoptosis of monolayer breast cancer MCF-7 cells. *Anticancer Res.* 2005;25:4187-4196.

27. Ghoneum M, Hamilton J, Brown J, Gollapudi S. Human squamous cell carcinoma of the tongue and colon undergoes apoptosis upon phagocytosis of *Saccharomyces cerevisiae*, the baker’s yeast, in vitro. *Anticancer Res.* 2005;25:981-989.

28. Ghoneum M, Brown J, Gollapudi S. Yeast therapy for the treatment of cancer and its enhancement by MGN-3/Biobran, an arabinoxylan rice bran. In: Demasi AR, ed. *Cellular Signaling and Apoptosis Research*. New York, NY: Nova Science; 2007:185-200.

29. Ghoneum M, Wang L, Agrawal S, Gollapudi S. Yeast therapy for the treatment of breast cancer: a nude mice model study. *In Vivo*. 2007;21:251-258.

30. Ghoneum M, Badr El-Din NK, Noaman E, Tolentino L. *Saccharomyces cerevisiae*, the baker’s yeast, suppresses the growth of Ehrlich carcinoma-bearing mice. *Cancer Immunol Immunother.* 2008;57:581-592.

31. Kuo LJ, Yang LX. Gamma-H2AX—a novel biomarker for DNA double-strand breaks. In: Demasi AR, ed. *Cellular Signaling and Apoptosis Research*. New York, NY: Nova Science; 2007:185-200.

32. Kuo LJ, Yang LX. Gamma-H2AX—a novel biomarker for DNA double-strand breaks. *In Vivo*. 2008;22:305-309.

33. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. *Mol Cell*. 2010;39:8-24.

34. Gustafson DL, Long ME, Zirrolle JA, et al. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. *Cancer Chemother Pharmacol*. 2003;52:159-166.

35. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. *Drug Saf*. 2000;23:401-428.

36. Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. *Gastric Cancer*. 2017;20(suppl 1):111-121.

37. Mukai H, Kato K, Esaki T, et al. Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. *Invest New Drugs*. 2016;34:750-759.

38. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. *Clin Cancer Res*. 1995;1:599-606.

39. Bielopolski D, Evron E, Moreh-Rahav O, Landes M, Stemmer SM, Salamon F. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. *J Chemother*. 2017;29:113-117.

40. Bang MH, Van Riep T, Thinh NT, et al. Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial. *Anticancer Res.* 2010;30:5145-5151.

41. Gelsomino G, Corsetto PA, Campia I, et al. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. *Mol Cancer*. 2013;12:137.

42. Kuan CY, Walker TH, Luo PG, Chen CF. Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line. *J Am Coll Nutr*. 2011;30:265-273.

43. Abulrob AN, Mason M, Bryce R, Gumbleton M. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance. *J Drug Target*. 2000;8:247-256.

44. Yu XJ, Sun K, Tang XH, et al. Harmin combined with paclitaxel inhibits tumor proliferation and induces apoptosis through down-regulation of cyclooxygenase-2 expression in gastric cancer. *Oncol Lett*. 2016;12:983-988.

45. Gonçalves A, Braguer D, Carles G, André N, Prevôt C, Briand C. Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). *Biochem Pharmacol*. 2000;60:1579-1584.

46. Peng ZG, Liu DC, Yao YB, et al. Paclitaxel induces apoptosis in leukemia cells through a JNK activation-dependent pathway. *Genet Mol Res*. 2016;15:15013904.

47. Varbrio G, Veres B, Gallyas F Jr, Sumegi B. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. *Free Radiol Biol Med*. 2001;31:548-558.

48. Rodi DJ, Janes RW, Sanganee HJ, Holton RA, Wallace BA, Makowski L. Screening of a library of phage-displayed peptides identifies human Bel-2 as a Taxol-binding protein. *J Mol Biol*. 1999;285:197-203.

49. Hernández-Vargas H, Palacios J, Moreno-Bueno G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. *Oncogene*. 2007;26:2902-2913.

50. Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. *Mol Cancer Ther*. 2005;4:1495-1504.

51. Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV, Limtrakul P. Curcinumidin purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). *Cancer Chemother Pharmacol*. 2006;57:376-388.

52. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. Modulation of function of human multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. *Mol Cell Biochem*. 2007;306:85-95.

53. Chearwae W, Shukla S, Limtrakul P, Ambudkar SV. Modulation of the function of the multidrug resistance linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. *Mol Cancer Ther*. 2006;5:1995-2006.

54. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. *J Drug Target*. 2006;14:211-2130.

55. Bansal T, Jaggi M, Khar RK. Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. *J Pharm Pharm Sci*. 2009;12:46-78.